Healthcare >> CEO Interviews >> October 5, 2000
DR. H. JOSEPH REISER, President and Chief Executive Officer of CYTOGEN
Corporation, gained most of his pharmaceutical experience at Berlex
Laboratories, the US subsidiary of Schering AG, where he held positions
of increasing responsibility since 1981, culminating in his appointment
to Corporate Vice President and General Manager, Pharmaceuticals. In
1993 Berlex selected Dr. Reiser as its first Vice President of
Technology and Industry Relations. Prior to that time he was Vice
President of R&D responsible for preclinical research and development
activities. His initial assignment at Berlex was to build a drug
discovery effort via his appointment as Director of Pharmacology in
1981. Also during his tenure at Berlex, Dr. Reiser served as the first
President of Schering Berlin's Venture Corporation from 1993 to 1994,
where he secured funding participation in diverse areas of
pharmaceutical R&D and joint ventures. In addition, Dr. Reiser was
active in US-based and international licensing activities. Dr. Reiser
joined Cytogen in August 1998 and has since that time lead the strategic
repositioning of Cytogen in the area of oncology and proteomics. Dr.
Reiser received his PhD in Physiology from Indiana University School of
Medicine, where he also earned his Master's and Bachelor's of Science
degrees. He has held various teaching positions and has been awarded
fellowships at the Likoff Cardiovascular Institute, the American Heart
Association (AHA) and the National Institutes of Health. He also has
served on Editorial Boards, on the Steering Committee of the
Pharmaceutical Manufacturers Association and the Boards of several
companies, including Berlex. He has authored more than 70 publications
and presentations. Profile
Dr. Reiser: CYTOGEN is a well-established biopharmaceutical company
which recently celebrated 20 years of existence. Historically,
